OverviewChartNewsTraderScreen

HSBC TUR.WAR.OP.END. AYJ/  DE000TT8QAH9  /

gettex Zettex2
2024-09-20  9:36:37 PM Chg.+0.0100 Bid9:58:13 PM Ask- Underlying Strike price Expiration date Option type
2.8400EUR +0.35% 2.8400
Bid Size: 15,000		 -
Ask Size: -		 VALNEVA SE EO... 30.5104 EUR 2078-12-31 Put
GlobeNewswire 09-03 Valneva and Pfizer Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidat...
GlobeNewswire 08-13 Valneva Reports Half Year 2024 Financial Results and Provides Corporate Updates
GlobeNewswire 08-01 Valneva and LimmaTech Enter into a Strategic Partnership to Accelerate the Development of the World’...
GlobeNewswire 07-22 CEPI Expands Partnership with Valneva with a $41.3 Million Grant to Support Broader Access to the Wo...
GlobeNewswire 07-17 Phase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary Vaccination Series Completion ...
GlobeNewswire 07-01 Valneva Receives Marketing Authorization in Europe for the World’s First Chikungunya Vaccine, IXCHIQ...
GlobeNewswire 06-26 Valneva Announces Successful Outcome of its Combined General Meeting and Appointment of a New Direct...
GlobeNewswire 06-24 Valneva Announces Health Canada Approval of the World’s First Chikungunya Vaccine, IXCHIQ®
GlobeNewswire 06-05 Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Co...
GlobeNewswire 06-04 Valneva to Present and Hold Investor Meetings at Upcoming Conferences in June
GlobeNewswire 06-03 Valneva Announces Publication of Lyme Disease Phase 2 Trials in the Lancet Infectious Diseases
GlobeNewswire 05-31 Valneva Receives EMA’s Positive CHMP Opinion for its Chikungunya Vaccine
GlobeNewswire 05-21 Valneva Appoints Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer
GlobeNewswire 05-13 Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents for its Single-Shot Chikungunya...
GlobeNewswire 05-07 Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates
GlobeNewswire 03-26 Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate
GlobeNewswire 03-25 Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F
GlobeNewswire 03-21 Valneva to Present on its Chikungunya Vaccine IXCHIQ®, Participate in Multiple Events at the 24th Wo...
GlobeNewswire 03-20 Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook
GlobeNewswire 03-18 Valneva Announces Extension of the Interest-Only Period of Its Debt Facility with Deerfield and Orbi...
GlobeNewswire 03-04 Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences
GlobeNewswire 02-29 U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva’s Single-Dose Chikungunya Vaccine IXCHI...
GlobeNewswire 02-15 Valneva Reports Full Year 2023 Revenue and Cash, Provides First 2024 Guidance
GlobeNewswire 02-05 Valneva Announces Sale of Priority Review Voucher for $103 Million
GlobeNewswire 01-10 Valneva Vaccinates First Participant in Pediatric Trial of Single-Shot Chikungunya Vaccine